Last reviewed · How we verify
Extended Letrozole Therapy
At a glance
| Generic name | Extended Letrozole Therapy |
|---|---|
| Sponsor | GABRIEL MONTEIRO PINHEIRO |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (PHASE3)
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study (PHASE3)
- Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS) (NA)
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (PHASE3)
- Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (PHASE2)
- Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen (PHASE1, PHASE2)
- Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended Letrozole Therapy CI brief — competitive landscape report
- Extended Letrozole Therapy updates RSS · CI watch RSS
- GABRIEL MONTEIRO PINHEIRO portfolio CI